PCT/US14/15574 and US Patent Application 14/177,866,2014
NON-CONFIDENTIAL INVENTION SUMMARY
Priority Date: February 11, 2013
John Hiscott, Ph.D., Vaccine & Gene Therapy Institute of Florida
Rongtuan Lin Ph.D., Jewish General Hospital, Montreal, Quebec
The innate immune system has evolved numerous molecular sensors and signaling pathways to detect, contain, and clear viral infections and therefore these pathways are useful in adjuvant development for vaccines. This invention embodies oligoribonucleotide RIG-1 agonists derived from the 5' and 3'UTRs of the VSV genome that activates the RIG-1 signaling pathway and triggers a robust antiviral response that interferes with infection by several pathogenic viruses, including Dengue, HCV, HIV-1 and H1N1 Influenza A/PR/8/34. Furthermore, intravenous delivery of this RIG-1 agonist stimulates an antiviral state in in vivo mouse studies and has the potential to be a potent adjuvant as evidenced by its protection of mice from lethal influenza virus challenge.
Also included are modified variants of 5'ppp sequence and methods of treating a viral infection in a subject by administering one or more of the pharmaceutical compositions to a subject are claimed.
Key Words: Influenza, antiviral therapy, innate immunity, 5’pppRNA, adjuvant
Publication: Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. Goulet ML,et.al PLoS Pathog. 2013 Apr;9(4):e1003298.
Contact: Catherine E. Vorwald, Executive Director, Marketing and Business Development
Office: (772) 345-5633 Mobile (772) 353-0315
5'-Triphosphate Oligoriboncleotides: for Antiviral Therapy
(1824 Non Confidential Summary RIG-1…)